>

MEETINGS / EVENTS

RSS

November 08 - 09 2014, 12:00 AM - 12:00 AM

ASA Quality Meeting 2014

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

June 26 - 28 2015, 12:00 AM - 12:00 AM

Annual Perioperative Surgical Home Summit

>

FDA MEDWATCH ALERTS

October 16, 2014

FDA MedWatch - LifeCare Flexible Intravenous Solutions by Hospira, Inc.: Recall - Potential for Leakage

Summary:

FDA MedWatch LifeCare Flexible Intravenous Solutions by Hospira Inc

October 13, 2014

FDA MedWatch - CareFusion EnVe and ReVel Ventilators: Class 1 Recall - Power Connection Failure

Summary:

FDA MedWatch CareFusion EnVe and ReVel Ventilators

October 13, 2014

FDA MedWatch - ICU Medical ConMed Stat2 Flow Controller: Class 1 Recall - Delivers Higher Flow Rate than Intended

Summary:

FDA MedWatch ICU Medical ConMed Stat2 Flow Controller

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

J&J Announces FDA Rejection of SEDASYS® Device

Chicago — (April 22, 2010) 

On Tuesday April 20, 2010 as reported by several media sources,1 2 Johnson & Johnson, parent company of Ethicon Endo Surgery, Inc., announced that the Food and Drug Administration (FDA) rejected its application for the SEDASYS® Computer-Assisted Personalized Sedation System. According to the reports, FDA sent the company a “not-approvable” letter after review of the application for, SEDASYS® which, through the use of a series of feedback and monitors, was designed to administer therapeutic levels of propofol to patients “undergoing colonoscopy and esophagoduodenoscopy procedures.”

The ASA had expressed concerns with the safety of the SEDASYS® system both in writing3 and during an FDA advisory panel hearing on the device back on May 28, 2009. However, following a presentation from the manufacturer and testimony from the public on the device, the advisory panel voted 8-2 that the device was “approvable with conditions.”4 Although reports indicate that the company will appeal the Agency’s decision, the final ruling contradicts the decision of the advisory panel and is a sound rejection of the application for the device.

In response to the news, ASA President, Dr. Alexander Hannenberg announced his strong support of the Agency’s decision and stated, “I am pleased that the FDA recognized the many unanswered questions and safety concerns about the device and the qualifications of those who sought to use it. ASA has a long history of advocating for patient safety and through its ruling on SEDASYS®, FDA has fulfilled its duty to protect patients; for that we are extremely grateful.”

  1. ASA comments to FDA
  2. FDA summary of the advisory committee meeting on May 28,2009

THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS

Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves.

For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/WhenSecondsCount. Join the ANESTHESIOLOGYTM 2014 social conversation today. Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES2014.

###

Contact:

American Society of Anesthesiologists
pr@asahq.org
847-825-5586